ValuEngine downgraded shares of Neurotrope Inc (OTCMKTS:NTRP) from a sell rating to a strong sell rating in a report issued on Thursday morning.

Separately, Aegis assumed coverage on Neurotrope in a research report on Wednesday, April 12th. They set a buy rating and a $31.00 price objective on the stock.

Shares of Neurotrope (OTCMKTS NTRP) opened at 4.82 on Thursday. The firm’s 50-day moving average is $7.26 and its 200-day moving average is $12.21. The firm’s market cap is $38.02 million. Neurotrope has a 1-year low of $4.40 and a 1-year high of $29.00.

COPYRIGHT VIOLATION NOTICE: “Neurotrope Inc (NTRP) Downgraded to Strong Sell at ValuEngine” was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/neurotrope-inc-ntrp-downgraded-to-strong-sell-at-valuengine/1463314.html.

An institutional investor recently bought a new position in Neurotrope stock. Spark Investment Management LLC purchased a new position in shares of Neurotrope Inc (OTCMKTS:NTRP) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 22,900 shares of the company’s stock, valued at approximately $214,000. Spark Investment Management LLC owned 0.29% of Neurotrope at the end of the most recent reporting period.

Neurotrope Company Profile

Neurotrope, Inc, formerly BlueFlash Communications, Inc, is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neurotrope Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.